Disclosures. CKD/ESRD care among vulnerable populations. Objectives. Case: Ms. S 3/12/2016. Delphine Tuot, MDCM, MAS Assistant Professor of Medicine

Size: px
Start display at page:

Download "Disclosures. CKD/ESRD care among vulnerable populations. Objectives. Case: Ms. S 3/12/2016. Delphine Tuot, MDCM, MAS Assistant Professor of Medicine"

Transcription

1 Disclosures CKD/ESRD care among vulnerable populations I have nothing to disclose Delphine Tuot, MDCM, MAS Assistant Professor of Medicine Objectives Recognize disparities related to kidney health Learn about early CKD management strategies that may be of particular importance in this patient population Appreciate that poor CKD awareness may contribute to suboptimal risk factor modification among vulnerable patients Learn strategies to alleviate the impact of homelessness on CKD/ESRD care 50yo AA woman PmHx: hypertension Case: Ms. S Meds: chlorthalidone 25mg daily PE: 125/75 mmhg, 80 bpm Older brother just initiated dialysis at age 58. She asks about her risk for dialysis. Is she at risk for CKD? Does she have CKD? 1

2 What is CKD? Why should you care? For every level of egfr, higher albuminuria confers higher mortality risk. Population: 14,586 NHANES participants ( ) 11.5% adult population 23 million adults Low egfr is associated with high mortality and CV morbidity All cause mortality Setting: KP of Northern California Go et al. NEJM Astor. Am J Epi Prognosis of CKD progression to ESRD by egfr and albuminuria categories. albuminuria categories (mg/g) CKD prevalence: racial/ethnic disparities Study population: NHANES adult participants, egfr categories (ml/min/1.73m 2 ) Levy, KI, USRDS Data Report,

3 CKD prevalence: racial/ethnic disparities Study population: NHANES adult participants, CKD prevalence: SES disparities Setting: community adults from 12 representative census tracts in Baltimore; equal numbers by sex, race, SES (high/low) Low SES: < 125% federal poverty level USRDS Data Report, 2015 Crews. AJKD, ESRD Incidence: race/ethnic disparities ESRD is nearly 3x greater among African Americans ESRD mortality: SES disparities Setting: 11,027 young adults initiating dialysis in US, Predictor: Neighborhood SES (>20% residents below FPL) Outcome: probability of survival Blacks have poor survival Low SES: Blacks vs Whites: ahr for mortality =1.52 ( ) High SES: Blacks vs. Whites: ahr for mortality =1.26 ( ) **slide courtesy of Neil Powe, MD USRDS Data Report, 2015 Johns, JASN,

4 CKD disparities: plausible mechanisms CKD disparities: plausible mechanisms System Patient Provider Traditional biological risk factors DM/HTN, obesity Genetics Non-traditional biologic risk factors Co-morbid diseases (HIV, HCV) Depression, substance abuse Periodontal disease Social determinants of health Poor patient CKD awareness/health related behaviors Mistrust of medical system Homelessness Health system barriers Poor access to care (insurance issues, fragmented care) Communication barriers Low PCP self-efficacy for managing CKD System Patient Provider Traditional biological risk factors DM/HTN, obesity Genetics Non-traditional biologic risk factors Co-morbid diseases (HIV, HCV) Depression, substance abuse Periodontal disease Social determinants of health Poor patient CKD awareness/health related behaviors Mistrust of medical system Homelessness Health system barriers Poor access to care (insurance issues, fragmented care) Communication barriers Low PCP self-efficacy for managing CKD Paradigm shift: early detection of CKD Screening for CKD 2013 ACP recommendation #1: No screening for CKD in asymptomatic adults without risk factors of CKD. Grade: weak recommendation, low quality evidence Strong risk factors for CKD morbidity/mortality Diabetes (presence and glycemic control) HTN (presence and control) Family history of ESRD Low socioeconomic status Racial/ethnic minorities Levy, AJKD, Qaseem,, Annals of IM

5 50yo AA woman PmHx: hypertension Case: Ms. S Meds: chlorthalidone 25mg daily PE: 125/75 mmhg, 80 bpm Labs: Cr=0.7 mg/dl; egfraa: >60 ml/min/1.73 m 2 UACR: 800mg/g You start AceInh (i.e., Benazepril 10mg daily) Now what? Titration of ACEi/ARB? 2013 ACP recommendation #2: No testing for proteinuria in adults with or without diabetes who are currently on an ACEi/ARB. Grade: weak recommendation, low quality evidence Setting: 298,875 Veterans, Predictor: UACR Outcome: mortality **Higher UACR is associated with greater mortality, independent of demographics, co morbidities, egfr, ACEi/ARB use. Qaseem, Annals of Int Med 2013; Csaba, JACC, Titration of ACEi/ARB? Setting: China, ROAD trial Study population: 360 non-diabetic patients with avg scr of 2.7 mg/dl Intervention: titration of ACEi/ARB vs. standard dose Summary thus far CKD is common Titration of ACEi/ARB in pts with moderate CKD was associated with decreased composite endpoint of ESRD, doubling scr, mortality, independent of BP control. Socioeconomic and racial/ethnic disparities exist egfr and albuminuria are both important Early detection in primary care is key Strongly consider screening for CKD in vulnerable populations Potential role for titration of ACEi/ARB to achieve maximum albuminuria suppression Hou. JASN,

6 Other CKD management strategies Aggressive BP control (target still not clear) < 130/80 mmhg if proteinuria < 140/90 mmhg without proteinuria Glycemic control Statin for CV risk reduction Lifestyle modifications Consult Nephrology egfr < 30 ml/min etiology of CKD is not clear Rapid CKD progression (loss of 5 ml/min/year) System CKD disparities: plausible mechanisms Patient Provider Traditional biological risk factors DM/HTN, obesity Genetics Non-traditional biologic risk factors Co-morbid diseases (HIV, HCV) Depression, substance abuse Periodontal disease Social determinants of health Poor patient CKD awareness/health related behaviors Mistrust of medical system Homelessness Health system barriers Poor access to care (insurance issues, fragmented care) Communication barriers Low provider self-efficacy for managing CKD and competing priorities Patient Awareness of CKD is low even among individuals with clinical markers of CKD National estimate of CKD awareness =6.0% Study population: 2292 NHANES participants with CKD; Percentage of CKD awareness and unawareness P for linear trend= Number of Clinical Manifestations of CKD Clinical markers Anemia Hyperkalemia Hyperphosphatemia Albuminuria Acidosis Elevated BUN Uncontrolled HTN Unawareness of CKD Awareness of CKD Plantinga, Archives Med. 2008; Tuot. CJASN,

7 Competing priorities and discomfort talking about CKD may contribute to poor awareness Setting: 15 low-income primary care clinics in/near Baltimore Study population: 236 patients with or at risk for CKD, largely AA Topics of conversation (% of visits) How should we describe CKD? Study population: 220 English and Spanish speaking patients with chronic diseases in safety-net primary care; 50% limited health literacy Percentages Aware Awareness questions Greer, AJKD, Tuot, Under review 25% pts with CKD/ESRD have limited health literacy Greater mortality among ESRD pts with low health literacy Low literacy Adequate health literacy Practical strategies to enhance CKD awareness Kidney Problem resonates well Protein in the urine Introduce within context of HTN/DM to encourage r9sk modification Pre-empt negative reactions Censoring: Total deaths = 103 (21%) Xplant = 29 (6%) Most people live normal lives with little kidney function. You are not near that point, but we need to work together to keep your kidneys as healthy as possible and prevent them from losing too much protein in the urine. Cavanaugh, JASN,

8 System CKD disparities: plausible mechanisms Patient Provider Traditional biological risk factors DM/HTN, obesity Genetics Non-traditional biologic risk factors Co-morbid diseases (HIV, HCV) Depression, substance abuse Periodontal disease Social determinants of health Poor patient CKD awareness/health related behaviors Mistrust of medical system Homelessness Health system barriers Poor access to care (insurance issues, fragmented care) Communication barriers Low provider self-efficacy for managing CKD and competing priorities Homelessness is a risk factor for ESRD/death among those with CKD Crude HR: 1.8 ( ) Adjusted HR: 1.28 ( ) Population: 15,353 adults with CKD in SF safety net; 6% were homeless Hall, CJASN, 2012 Among homeless populations, ESRD is associated with increased mortality Strategies to improve kidney care among homeless patients Refer patients to nephrology early Advocate for permanent (AVF/AVG) access placement Medication adherence Daily dosing; long-acting medications Pharmacy that delivers medi-sets to dialysis unit Partnering with Methadone dosing programs Dialysis adherence Late shift if needed for odd jobs Early shift if needed for shelter beds Transportation Case management programs Population: 558 homeless adults in Boston, Hwang, Archives,

9 Homelessness is a risk factor for late nephrology referrals Population: 460 patients who initiated dialysis at Grady hospital, Early referral: >3 mo Late referral: 1 3 mo Ultra late referral: <1 mo Strategies to improve kidney care among homeless patients Refer patients to nephrology early Advocate for permanent (AVF/AVG) access placement Medication adherence Daily dosing; long-acting medications Pharmacy that delivers medi-sets to dialysis unit Partnering with Methadone dosing programs Dialysis adherence Late shift if needed for odd jobs Early shift if needed for shelter beds Transportation Case management programs Obialo, AJKD, 2005 Take home points CKD is common, defined by egfr and albuminuria Socioeconomic disparities exist with respect to CKD/ESRD outcomes Patient, provider, system-level factors contribute to these suboptimal outcomes Small changes in practice can make a difference Screen among high-risk populations (low SES) Discuss CKD during visits Coordinate with care management programs to refer homeless patients to nephrology early and optimize care delivery for ESRD patients Thank You Delphine.Tuot@ucsf.edu 9

Updates in Chronic Kidney Disease Management. Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG

Updates in Chronic Kidney Disease Management. Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG Updates in Chronic Kidney Disease Management Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG No disclosures Research Funding: NIH, Blue Shield of California Foundation Objectives

More information

Chronic Kidney Disease

Chronic Kidney Disease Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease

More information

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA

More information

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Management of Early Kidney Disease: What to do Before Referring to the Nephrologist

Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing

More information

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO

More information

Update on HIV-Related Kidney Diseases. Agenda

Update on HIV-Related Kidney Diseases. Agenda Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED

More information

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Disclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

Disclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Outline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011

Outline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Disclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

Disclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Diabetic Kidney Disease in the Primary Care Clinic

Diabetic Kidney Disease in the Primary Care Clinic Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

Outline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012

Outline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Optimal blood pressure targets in chronic kidney disease

Optimal blood pressure targets in chronic kidney disease Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management

More information

Managing Progressive Kidney Disease Andrew S. Narva, MD

Managing Progressive Kidney Disease Andrew S. Narva, MD Managing Progressive Kidney Disease Andrew S. Narva, MD U.S. Department of Health and Human Services National Institute of Health Managing Progressive Kidney Disease Standards of care for patients with

More information

Chapter 1: CKD in the General Population

Chapter 1: CKD in the General Population Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table

More information

Chapter 2: Identification and Care of Patients With CKD

Chapter 2: Identification and Care of Patients With CKD Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease

More information

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December

More information

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease

More information

Chapter 2: Identification and Care of Patients With CKD

Chapter 2: Identification and Care of Patients With CKD Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,

More information

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,

More information

The vexing problem of suboptimal initiation of dialysis: Can we do better?

The vexing problem of suboptimal initiation of dialysis: Can we do better? Budapest Nephrology School August 30, 2010 The vexing problem of suboptimal initiation of dialysis: Can we do better? David C Mendelssohn Disclosures 2007 2010 Speaker Fees: Amgen, Ortho Biotech, Genzyme,

More information

Chapter 2: Identification and Care of Patients with CKD

Chapter 2: Identification and Care of Patients with CKD Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease

More information

CKDinform: A PCP s Guide to CKD Detection and Delaying Progression

CKDinform: A PCP s Guide to CKD Detection and Delaying Progression CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

Caring for the AKI Survivor: What is Required?

Caring for the AKI Survivor: What is Required? Caring for the AKI Survivor: What is Required? Ron Wald, MDCM MPH FRCPC Division of Nephrology St. Michael s Hospital and University of Toronto February 28, 2019 A patient in your ICU 65M with DM, HTN,

More information

Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions

Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of

More information

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,

More information

Screening and early recognition of CKD. John Ngigi (FISN) Kidney specialist

Screening and early recognition of CKD. John Ngigi (FISN) Kidney specialist Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

CKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology

CKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Kidney Disease, Hypertension and Cardiovascular Risk

Kidney Disease, Hypertension and Cardiovascular Risk 1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,

More information

Chronic kidney disease-what can you do and when to refer?

Chronic kidney disease-what can you do and when to refer? Chronic kidney disease-what can you do and when to refer? Dr Goh Heong Keong www.passpaces.com/kidney.htm Outline of Lecture Introduction Epidemiology of CKD in Malaysia/ World Complications of CKD What

More information

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS Objectives Heart failure and Hypertension Kirsten Bibbins-Domingo, PhD, MD, MAS Lee Goldman, MD Endowed Chair in Medicine Professor of Medicine and of Epidemiology and Biostatistics University of California,

More information

CKD and risk management : NICE guideline

CKD and risk management : NICE guideline CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of

More information

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2 Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to

More information

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets

More information

SLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota

SLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone

More information

Faculty/Presenter Disclosure

Faculty/Presenter Disclosure CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO

More information

Chronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US

Chronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US 1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine

More information

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

Objectives. Kidney Complications With Diabetes. Case 10/21/2015 Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

A New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta

A New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

Zuni Health Initiative

Zuni Health Initiative ZUNI JEWELRY Zuni Health Initiative Raj Shah-University of New Mexico vshah@salud.unm.edu Do' tse'mak i:k'oshudu, elek'yanna!!! May you feel better, everything will be alright!!! OBJECTIVES Describe the

More information

Case #1. Current Management Strategies in Chronic Kidney Disease. Serum creatinine cont. Pitfalls of Serum Cr

Case #1. Current Management Strategies in Chronic Kidney Disease. Serum creatinine cont. Pitfalls of Serum Cr Current Management Strategies in Chronic Kidney Disease Grace Lin, MD Assistant Professor of Medicine, University of California San Francisco Case #1 50 y.o. 70 kg man with long-standing hypertension is

More information

Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality

Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage

More information

Cardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology

Cardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology 49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in

More information

Creatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC

Creatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305

More information

Primary Care Physicians and Clinicians. XXX on behalf of the Upper Midwest Fistula First Coalition. Chronic Kidney Disease (CKD) Resources

Primary Care Physicians and Clinicians. XXX on behalf of the Upper Midwest Fistula First Coalition. Chronic Kidney Disease (CKD) Resources August 10, 2007 To: From: RE: Primary Care Physicians and Clinicians XXX on behalf of the Upper Midwest Fistula First Coalition Chronic Kidney Disease (CKD) Resources Caring for patients with chronic kidney

More information

What should you do next? Presenter Disclosure Information. Learning Objectives. Case: George

What should you do next? Presenter Disclosure Information. Learning Objectives. Case: George 2:45 3:45pm Optimizing the Management of Patients with Chronic Kidney Disease SPEAKER Jay B. Wish, MD, FACP Presenter Disclosure Information The following relationships exist related to this presentation:

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for

More information

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

The Elderly Patient with Low egfr: Beyond a Disease-Oriented Approach. Maroun Azar, M.D.

The Elderly Patient with Low egfr: Beyond a Disease-Oriented Approach. Maroun Azar, M.D. The Elderly Patient with Low egfr: Beyond a Disease-Oriented Approach Maroun Azar, M.D. Disclosures None, no conflicts of interest Some of the Arguments Are current definitions of CKD accurate in the

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Modern Management of Hypertension: Where Do We Draw the Line?

Modern Management of Hypertension: Where Do We Draw the Line? Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure

More information

CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR

CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR OUTLINE: A journey through CKD Screening for CKD: The why,

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Blood Pressure Monitoring in Chronic Kidney Disease

Blood Pressure Monitoring in Chronic Kidney Disease Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Jai R adhakrishnan, Radhakrishnan, MD Columbia University

Jai R adhakrishnan, Radhakrishnan, MD Columbia University Jai Radhakrishnan, MD Jai Radhakrishnan, MD Columbia University 1. The Patient-Centered Medical Home 2. CKD Clinic as the paradigm for PCMH? 3. Outcome data 4. The Columbia model 5. Limitations 6. Financial

More information

KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64

KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64 211 Summary Figures S4 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated

More information

Long-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota

Long-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota Long-term Non-ESRD Kidney Donor Risks Arthur Matas Dept Surgery University of Minnesota Conflict of Interest Disclosure I have no relevant financial relationships to disclose No off label use will be discussed

More information

Outpatient Management of Chronic Kidney Disease for the Internist

Outpatient Management of Chronic Kidney Disease for the Internist Outpatient Management of Chronic Kidney Disease for the Internist Annual Meeting of Maryland Chapter of the American College of Physicians February 3, 2018 MARY (TESSIE) BEHRENS, MD, FACP, FASN, FNKF MID-ATLANTIC

More information

Chronic kidney disease (CKD) has received

Chronic kidney disease (CKD) has received Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:

More information

Identifying and Managing Chronic Kidney Disease: A Practical Approach

Identifying and Managing Chronic Kidney Disease: A Practical Approach Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,

More information

Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly?

Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University

More information

KEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56

KEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56 21 Summary Figures S32 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated blood glucose (WHO); fasting blood sugar

More information

Status of the CKD and ESRD treatment: Growth, Care, Disparities

Status of the CKD and ESRD treatment: Growth, Care, Disparities Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Screening for Chronic Kidney Disease: Time to Say No

Screening for Chronic Kidney Disease: Time to Say No Screening for Chronic Kidney Disease: Time to Say No Charles P. Vega, MD Disclosures February 27, 2014 Introduction Chronic kidney disease (CKD) is common and often asymptomatic at the time of diagnosis.

More information

Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin

Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this

More information

Hypertension and Chronic Kidney Disease

Hypertension and Chronic Kidney Disease Hypertension and Chronic Kidney Disease George Bakris, MD, F.A.S.N. Professor of Medicine Director, Hypertensive Diseases Unit University of Chicago School of Medicine Projected growth of the incident

More information

Evaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands

Evaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands Evaluation of Chronic Kidney Disease Paul E de Jong University Medical Center Groningen The Netherlands Evaluation and Management of CKD 1. Definition and classification of CKD 2. Definition and impact

More information

Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria

Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,

More information

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College

More information

Section Questions Answers

Section Questions Answers Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension

More information

Contrast-Induced Nephropathy: Evidenced Based Prevention

Contrast-Induced Nephropathy: Evidenced Based Prevention Contrast-Induced Nephropathy: Evidenced Based Prevention Michael J Cowley, MD, FSCAI Nothing to disclose Contrast-Induced Nephropathy (CIN) Definitions New onset or worsening of renal function after contrast

More information

CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College

CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)

More information

Chapter 1: CKD in the General Population

Chapter 1: CKD in the General Population Chapter 1: CKD in the General Population In light of the 2017 blood pressure guidelines from the American College of Cardiology/American Heart Association (ACC/AHA), this year we examine hypertension control

More information

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space? Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09

More information

Treating Hypertension from

Treating Hypertension from Treating Hypertension from Initiation to Resistance: A Case Study Approach Michelle Krause, MD Division of Nephrology University of Arkansas for Medical Sciences Central Arkansas Veteran s Healthcare System

More information

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist

More information

EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas

EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas Disclosure of Interests AstraZeneca (scientific advisory board) Bayer

More information

Cardiovascular Risk Reduction in Kidney Transplant Recipients

Cardiovascular Risk Reduction in Kidney Transplant Recipients Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):

More information

Office Management of Reduced GFR Practical advice for the management of CKD

Office Management of Reduced GFR Practical advice for the management of CKD Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE

More information

Interventions to reduce progression of CKD what is the evidence? John Feehally

Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think

More information

THE CONSERVATIVE CARE PATHWAY

THE CONSERVATIVE CARE PATHWAY THE CONSERVATIVE CARE PATHWAY Dr. Gaylene Hargrove Sept. 19, 2015 Island Health Renal Program End of Life Conference Learning Objectives Describe and discuss what defines conservative care. Identify key

More information

Applying clinical guidelines treating and managing CKD

Applying clinical guidelines treating and managing CKD Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012

More information

Modern Management of Hypertension

Modern Management of Hypertension Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence

More information

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing

More information

KEEP 2009 Summary Figures

KEEP 2009 Summary Figures S4 29 Summary Figures American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 21:pp S4-S57 S41 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving

More information

Session 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives

Session 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives Session 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives 1. Understand the impact of chronic kidney disease (CKD) as a common condition of the adult US population.

More information